BACKGROUND: Hepatic encephalopathy (HE) can adversely affect outcomes in both in-patients and out-patients with cirrhosis. AIM: To define targets for improving quality of care in HE management in the multi-centre North American Consortium for End-Stage Liver Disease (NACSELD) cohort. METHOD: NACSELD in-patient cohort was analysed for (a) medication-associated precipitants, (b) aspiration pneumonia development, (c) HE medication changes, and (d) 90-day HE recurrence/readmissions. Comparisons were made between patients on no-therapy, lactulose only, rifaximin only or both. Ninety-day HE-readmission analysis was adjusted for MELD score. RESULTS: Two thousand eight hundred and ten patients (1102 no-therapy, 659 lactulose, 154 rifaximin, 859 both) were included. HE on admission, and HE rates during hospitalisation were highest in those on lactulose only or dual therapy compared to no-therapy or rifaximin only (P < 0.001). Medications were the most prevalent precipitants (32%; 21% lactulose over/underuse, 5% benzodiazepines, 4% opioids, 1% rifaximin underuse, 1% hypnotics). Patients with medication-associated precipitants had a better prognosis compared to other precipitants. A total of 23% (n = 217) reached grade 3/4 HE, of which 16% developed HE-related aspiration pneumonia. Two thousand four hundred and twenty patients were discharged alive without liver transplant (790 no-therapy, 639 lactulose, 136 rifaximin, 855 both); 12.5% (n = 99) of no-therapy patients did not receive a discharge HE therapy renewal. Ninety-day HE-related readmissions were seen in 16% of patients (9% no-therapy, 9% rifaximin only, lactulose only 18%, dual 21%, <0.001), which persisted despite MELD adjustment (P = 0.009). CONCLUSION: Several targets to improve HE management were identified in a large cohort of hospitalised cirrhotic patients. Interventions to decrease medication-precipitated HE, prevention of aspiration pneumonia, and optimisation of HE medications are warranted.
BACKGROUND:Hepatic encephalopathy (HE) can adversely affect outcomes in both in-patients and out-patients with cirrhosis. AIM: To define targets for improving quality of care in HE management in the multi-centre North American Consortium for End-Stage Liver Disease (NACSELD) cohort. METHOD:NACSELD in-patient cohort was analysed for (a) medication-associated precipitants, (b) aspiration pneumonia development, (c) HE medication changes, and (d) 90-day HE recurrence/readmissions. Comparisons were made between patients on no-therapy, lactulose only, rifaximin only or both. Ninety-day HE-readmission analysis was adjusted for MELD score. RESULTS: Two thousand eight hundred and ten patients (1102 no-therapy, 659 lactulose, 154 rifaximin, 859 both) were included. HE on admission, and HE rates during hospitalisation were highest in those on lactulose only or dual therapy compared to no-therapy or rifaximin only (P < 0.001). Medications were the most prevalent precipitants (32%; 21% lactulose over/underuse, 5% benzodiazepines, 4% opioids, 1% rifaximin underuse, 1% hypnotics). Patients with medication-associated precipitants had a better prognosis compared to other precipitants. A total of 23% (n = 217) reached grade 3/4 HE, of which 16% developed HE-related aspiration pneumonia. Two thousand four hundred and twenty patients were discharged alive without liver transplant (790 no-therapy, 639 lactulose, 136 rifaximin, 855 both); 12.5% (n = 99) of no-therapy patients did not receive a discharge HE therapy renewal. Ninety-day HE-related readmissions were seen in 16% of patients (9% no-therapy, 9% rifaximin only, lactulose only 18%, dual 21%, <0.001), which persisted despite MELD adjustment (P = 0.009). CONCLUSION: Several targets to improve HE management were identified in a large cohort of hospitalised cirrhotic patients. Interventions to decrease medication-precipitated HE, prevention of aspiration pneumonia, and optimisation of HE medications are warranted.
Authors: J S Bajaj; J Cordoba; K D Mullen; P Amodio; D L Shawcross; R F Butterworth; M Y Morgan Journal: Aliment Pharmacol Ther Date: 2011-02-09 Impact factor: 8.171
Authors: Jasmohan S Bajaj; Leroy R Thacker; Douglas M Heuman; Richard K Sterling; R Todd Stravitz; Arun J Sanyal; Velimir Luketic; Michael Fuchs; Ho Chong S Gilles; James B Wade Journal: Liver Transpl Date: 2012-10 Impact factor: 5.799
Authors: Alina M Allen; W Ray Kim; James P Moriarty; Nilay D Shah; Joseph J Larson; Patrick S Kamath Journal: Hepatology Date: 2016-10-20 Impact factor: 17.425
Authors: Kevin D Mullen; Arun J Sanyal; Nathan M Bass; Fred F Poordad; Muhammad Y Sheikh; R Todd Frederick; Enoch Bortey; William P Forbes Journal: Clin Gastroenterol Hepatol Date: 2013-12-21 Impact factor: 11.382
Authors: James G Orr; Craig J Currie; Ellen Berni; Anurag Goel; Kieran J Moriarty; Ashish Sinha; Fiona Gordon; Anne Dethier; John F Dillon; Katie Clark; Paul Richardson; Paul Middleton; Vishal Patel; Debbie Shawcross; Helen Preedy; Richard J Aspinall; Mark Hudson Journal: Liver Int Date: 2016-04-05 Impact factor: 5.828
Authors: Debbie L Shawcross; Arthur A Dunk; Rajiv Jalan; Gerald Kircheis; Robert J de Knegt; Wim Laleman; John K Ramage; Heiner Wedemeyer; Ian E J Morgan Journal: Eur J Gastroenterol Hepatol Date: 2016-02 Impact factor: 2.566
Authors: Jeremy Louissaint; Katie Grzyb; Linda Bashaw; Rima A Mohammad; Neehar D Parikh; Elliot B Tapper Journal: Am J Gastroenterol Date: 2022-03-01 Impact factor: 12.045
Authors: Christian Labenz; Gerrit Toenges; Jörn M Schattenberg; Michael Nagel; Yvonne Huber; Jens U Marquardt; Joachim Labenz; Peter R Galle; Marcus-Alexander Wörns Journal: Clin Transl Gastroenterol Date: 2020-06 Impact factor: 4.396
Authors: Paolo Caraceni; Victor Vargas; Elsa Solà; Carlo Alessandria; Koos de Wit; Jonel Trebicka; Paolo Angeli; Rajeshwar P Mookerjee; François Durand; Elisa Pose; Aleksander Krag; Jasmohan S Bajaj; Ulrich Beuers; Pere Ginès Journal: Hepatology Date: 2021-06-07 Impact factor: 17.425